Esketamine Nasal Spray vs Quetiapine Extended-Release
<b>Conclusion:</b> Among employed adults with TRD, esketamine treatment was associated with significantly larger improvements in WPL and related costs compared to quetiapine, suggesting greater benefits from patient well-being and employer perspectives.
Authors
- Yordan Godinov
- Maryia Zhdanava (ORCID: https://orcid.org/0000-0002-7995-2578)
- Hannah E. Bowrey (ORCID: https://orcid.org/0000-0002-3774-4201)
- Amanda Teeple
- Kristin K. Clemens (ORCID: https://orcid.org/0000-0001-9636-5597)
- Jozefien Buyze (ORCID: https://orcid.org/0000-0001-6780-380X)
- Kruti Joshi (ORCID: https://orcid.org/0000-0001-9263-5158)
- Aditi Shah
- Dominic Pilon (ORCID: https://orcid.org/0000-0002-6093-7167)
Institutions
- Johnson & Johnson (United States) (US)
- Janssen (Belgium) (BE)
- Health Solutions (Sweden) (SE)
- Group for Research in Decision Analysis (CA)
Publication Details
- Journal
- The Journal of Clinical Psychiatry
- Published
- 2025-01-27
- DOI
- https://doi.org/10.4088/jcp.24m15425
- Citations
- 2
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 2.79
Funders
- Janssen Scientific Affairs